Trial Profile
A Phase 1/2 Study Of The Efficacy, Safety, And Pharmacokinetics Of Oral PD-0332991, A Cyclin-Dependent Kinase 4 And 6 (CDK4/6) Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Dec 2021
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Letrozole
- Indications Adenocarcinoma; Advanced breast cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 23 Nov 2018 Status changed from active, no longer recruiting to completed.
- 18 Jun 2018 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
- 01 Mar 2018 Results of phase II portion of a phase I/II trial (n=42; Data cut-off March 4, 2016) published in the Cancer Science.